Journal Mobile Options
Table of Contents
Vol. 13, No. 2, 2002
Issue release date: February 2002
Dement Geriatr Cogn Disord 2002;13:67–73
(DOI:10.1159/000048636)

Efficacy of Olanzapine in the Treatment of Psychosis in Dementia with Lewy Bodies

Cummings J.L. · Street J. · Masterman D. · Clark W.S.
Departments of aNeurology and bPsychiatry and Biobehavioral Sciences, UCLA School of Medicine, Los Angeles, Calif., and cLilly Research Laboratories, Eli Lilly Co., Indianapolis, Ind., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective: This study sought to determine whether patients with dementia with Lewy bodies (DLB) and psychosis responded to treatment with olanzapine. Methods: This was a post hoc analysis of a subgroup of patients with DLB included in a larger double-blind, placebo-controlled, randomized parallel group trial of olanzapine for the treatment of psychosis in patients with Alzheimer’s disease. Patients meeting the consensus criteria for DLB and exhibiting parkinsonism and visual hallucinations were selected from the initial study. Psychosis was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS). Extrapyramidal symptoms were evaluated with the Simpson-Angus scale. Results: Twenty-nine patients met the criteria for DLB; 10 were randomized to placebo, 5 received 5 mg of olanzapine, 7 received 10 mg of olanzapine and 7 received 15 mg of olanzapine. Patients with DLB treated with 5 mg of olanzapine showed significant reductions in delusions and hallucinations. Patients treated with 10 mg showed a significant reduction in the NPI-NH delusion subscale score. No significant differences were found between the 15-mg group and the placebo group. Confirmatory findings emerged from an analysis of the BPRS. Caregivers reported decreased disruptions in their occupational routines for the group receiving 5 or 10 mg of olanzapine. There was no significant exacerbation of parkinsonian symptoms in any study group, no decrement in Mini-Mental State Examination scores in any of the treatment groups, and symptoms suggestive of anticholinergic toxicity did not differ among treatment groups. Conclusions: This preliminary analysis suggests that olanzapine (5 or 10 mg) reduces psychosis in patients with DLB without worsening parkinsonism.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Klatka LA, Louis ED, Schiffer RB: Psychiatric features in diffuse Lewy body disease: A clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology 1996;47:1148–1152.
  2. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 1996;47:1113–1124.
  3. Ala TA, Yang K-H, Sung JH, Frey WH 2nd: Hallucinations and signs of parkinsonism help distinguish patients with dementia and cortical Lewy bodies from patients with Alzheimer’s disease at presentation: A clinicopathological study. J Neurol Neurosurg Psychiatry 1997;62:16–21.
  4. Ballard C, Holmes C, McKeith I, et al: Psychiatric morbidity in dementia with Lewy bodies: A prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry 1999;156:1039–1045.
  5. Weiner MF, Risser RC, Cullum CM, et al: Alzheimer’s disease and its Lewy body variant: A clinical analysis of postmortem verified cases. Am J Psychiatry 1996;153:1269–1273.

    External Resources

  6. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E: Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673–678.
  7. Street J, Clark WS, Gannon KS, et al: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer’s disease in nursing care facilities. Arch Gen Psychiatry 2000;57:968–976.
  8. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
  9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  10. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients by the clinician. J Psychiatric Res 1975;12:189–198.
  11. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gorbien J: The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
  12. Wood S, Cummings JL, Hsu M-A, et al: Neuropsychiatric disturbances in nursing home residents: Characterization and measurement. Am J Geriatr Psychiatry 2000;8:75–83.
  13. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998;50:136–145.
  14. Sano M, Ernesto C, Thomas RG, et al: A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 1997;336:1216–1222.
  15. Morris JC, Cyrus PA, Orazem J, et al: Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998;50:1222–1230.
  16. Rogers SL, Friedhoff LT: The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7:293–303.
  17. Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–2276.
  18. Raskind MA, Peskind ER, Wessel T, Yuan W: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000;54:2261–2268.
  19. Cummings JL, Cyrus PA, Bieber F, et al: Metrifonate treatment of the cognitive deficits of Alzheimer’s disease. Neurology 1998;50:1214–1221.
  20. Corey-Bloom J, Anand R, Veach J, for the ENA 713 B352 Study Group: A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1998;1:55–65.
  21. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970;212:11–19.
  22. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799–812.
  23. Bymaster FP, Calligaro DO, Falcone JF, et al: Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87–96.
  24. Langlais PJ, Thal L, Hansen L, Galasko D, Alford M, Masliah E: Neurotransmitters in basal ganglia and cortex of Alzheimer’s disease with and without Lewy bodies. Neurology 1993;43:1927–1934.
  25. Perry EK, Irving D, Kerwin JM, et al: Cholinergic transmitter and neurotrophic activities in Lewy body dementia: Similarity to Parkinson’s and distinction from Alzheimer disease. Alzheimer Dis Assoc Disord 1993;2:69–79.
  26. O’Donnell BF, Drachman DA, Barnes HJ, Peterson KE, Swearer JM, Lew RA: Incontinence and troublesome behaviors predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992;5:45–52.
  27. Steele C, Rovner B, Chase GA, Folstein M: Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990;147:1049–1051.
  28. Chandler JD, Chandler JE: The prevalence of neuropsychiatric disorders in a nursing home population. J Geriatr Psychiatry Neurol 1988;1:71–76.

    External Resources

  29. Rovner BW, German PS, Broadhead J, et al: The prevalence and management of dementia and other psychiatric disorders in nursing homes. Int Psychogeriatr 1990;2:13–24.
  30. Wagner AW, Teri L, Orr-Rainey N: Behavior problems among dementia residents in special care units: Changes over time. J Am Geriatr Soc 1995;43:784–787.
  31. Hallberg IR, Norbert A: Nurses’ experiences of strain and their reactions in the care of severely demented patients. Int J Geriatr Psychiatry 1995;10:757–766.
  32. Holmes D, Teresi JA: Relating personnel costs in special care units and in traditional care units to resident characteristics. J Ment Health Policy Econ 1998;1:31–40.
  33. Malone ML, Thompson L, Goodwin JS: Aggressive behaviors among the institutionalized elderly. J Am Geriatr Soc 1993;41:853–856.
  34. Rovner BW, Steele CD, German P, Clark R, Folstein MF: Psychiatric diagnosis and uncooperative behavior in nursing homes. J Geriatr Psychiatry Neurol 1992;5:102–105.
  35. Aarsland D, Bronnick K, Karlsen K: Donepezil for dementia with Lewy bodies: A case study. Int J Geriatr Psychiatry 1999;14:69–72.
  36. Kaufer DI, Catt KE, Lopez OL, DeKosky ST: Dementia with Lewy bodies: Response of delirium-like features to donepezil. Neurology 1998;51:1512.
  37. Shea C, MacKnight C, Rockwood K: Aspects of dementia: Donepezil for treatment of dementia with Lewy bodies: A case series of nine patients. Int Psychogeriatr 1998;10:229–238.
  38. McKeith I, Del Ser T, Spano PF, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R: Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031–2036.
  39. Allen RL, Walker Z, D’Ath PJ, Katona CLE: Risperidone for psychotic and behavioural symptoms in Lewy body dementia. Lancet 1995;346:185.
  40. Chacko RC, Hurley RA, Jankovic J: Clozapine use in diffuse Lewy body disease. J Neuropsychiatry Clin Neurosci 1993;5:206–208.
  41. Geizer M, Ancill RJ: Combination of risperidone and donepezil in Lewy body dementia. Can J Psychiatry 1998;43:421–422.
  42. Burke WJ: Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998;10:227–229.

    External Resources

  43. Walker Z, Grace J, Overshot R, et al: Olanzapine in dementia with Lewy bodies: A clinical study. Int J Geriatr Psychiatry 1999;14:459–466.
  44. Mega MS, Masterman DL, Benson DF, et al: Dementia with Lewy Bodies: Reliability and validity of clinical and pathologic criteria. Neurology 1996;47:1403–1409.
  45. Litvan I, MacIntyre A, Goetz CG, et al: Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies. Arch Neurol 1998;55:969–978.
  46. McKeith IG, Fairbairn AF, Bothwell RA, et al: An evaluation of the predictive validity and inter-rater reliability of clinical diagnostic criteria for senile dementia of the Lewy body type. Neurology 1994;44:872–877.
  47. Papka M, Rubio A, Schiffer RB, Cox C: Lewy body disease: Can we diagnose it? J Neuropsychiatry Clin Neurosci 1998;10:405–412.
  48. Gomez-Isla T, Growdon WB, McNamara M, et al: Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies. Neurology 1999;53:2003–2009.
  49. Verghese J, Crystal HA, Dickson DW, Lipton RB: Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999;53:1974–1982.
  50. McKeith IG, Ballard CG, Perry RH, et al: Prospective validation of Consensus criteria for the diagnosis of dementia with Lewy bodies. Neurology 2000;54:1050–1058.
  51. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J: Diagnostic accuracy of dementia with Lewy bodies. Arch Neurol 2000;57:347–351.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50